2012-10-10 15:30:13 -

By David Moskowitz

Notwithstanding the take-out chatter on Illumina (NASDAQ:ILMN), with the
potential that Roche (OTC:RHHBY) may take another run at the company for $60 a
share (read more in PropThink's previous article), analysts are out with recent
commentary that ILMN's business is performing well, which could drive the stock
higher. Two broker dealers, Piper Jaffray and Leerink Swan, have each surveyed
labs that use sequencing equipment and published on the results Tuesday and
today, respectively, with the broad themes indicating that ILMN's HiSeq product
line may have stabilized (previously in decline) and new customer upgrades could
enable revenues to beat estimates over the next several quarters. Additionally,
the MiSeq sequencing line continues to gain traction, and is the preferred
system when users seek to order desktop-based sequencers. Both analysts note
that   3Q is looking solid, hinting that Consensus revenue and earnings estimates
are conservative (3Q Rev. and EPS estimates are $284.4M and $0.39,
respectively). Expect ILMN shares to get a lift from optimism on the business,
as well as the chance for earnings upside, with the added benefit that a Roche
take out bid could surface. Analysts have mixed opinions on whether the Roche
interest is real, but given that ILMN continues to posture as a willing seller,
and Roche has clearly demonstrated its interest in ILMN in the past, we are
believers.

See this article in its original form.

About PropThink

PropThink is an intelligence service that delivers long and short trading ideas
to investors in the healthcare and life sciences sectors. Our focus is on
identifying and analyzing technically-complicated companies and equities that
are grossly over or under-valued. We offer daily market coverage, weekly feature
stories, and a newsletter to investors who subscribe on PropThink.com. To learn
more, follow us on Twitter or visit us at  www.propthink.com.

Disclaimer:

You should assume that as of the publication date of any report or letter,
PropThink, LLC and persons or entities with whom it has relation ships
(collectively referred to as "PropThink") has a position in all stocks (and/or
options of the stock) covered herein that is consistent with the position set
forth in our research report. Following publication of any report or
letter, PropThink intends to continue transacting in the securities covered
herein, and we may be long, short, or neutral at any time hereafter regardless
of our initial recommendation. To the best of our knowledge and belief, all
information contained herein is accurate and reliable, and has been obtained
from public sources we believe to be accurate and reliable, and not from company
insiders or persons who have a relationship with company insiders. PropThink was
not compensated to publish this article. Our full disclaimer is available
at  www.propthink.com/disclaimer.




This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: PropThink via Thomson Reuters ONE
[HUG#1648065]